Close Menu

immunoaffinity mass spectrometry

The company plans to offer the immuno-MRM assays as kits covering sample prep and protein digestion as well as immuno-enrichment of specific peptides.

The company, called SISCAPA Assay Technologies, will offer assay development to pharmas and CROs and has tapped antibody firm Epitomics to produce reagents for the system and sell SISCAPA kits. So far, the company has licensed the technology to Pfizer for internal use.

The technique is useful for monitoring protein biomarkers in order to better understand target pathways and molecules as well building pharmacokinetic and pharmacodynamic models, said a company scientist.

The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.

US tax agency says 23andMe's genetic health test can be claimed as a medical expense for tax purposes, the Wall Street Journal reports.

Two Democratic lawmakers argue at USA Today that independent science is under attack by the Trump Administration.

In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.